Bioxytran (BIXT) Registration Filing summary

Company overview and business model

• Clinical-stage pharmaceutical company developing drugs for hypoxia-related conditions and viral diseases, with lead candidates BXT-25 (acellular oxygen carrier for stroke) and ProLectin (galectin antagonist for COVID-19 and other viral infections).

• Operations include subsidiaries focused on R&D, IP management, and clinical trials in the US, India, and BVI.

• Strategy centers on advancing drug candidates through early-stage trials and licensing to larger pharmaceutical partners for commercialization.

Financial performance and metrics

• No revenues to date; accumulated deficit of $18.4 million as of September 30, 2024.

• Net loss for the nine months ended September 30, 2024, was $1.86 million, down from $3.44 million in the prior year period, primarily due to reduced R&D and management salary cuts.

• Cash on hand was $34,672 at September 30, 2024, with negative working capital of $1.2 million.

• R&D expenses for the nine months ended September 30, 2024, were $78,000, reflecting a significant reduction due to lack of funding.

• Convertible notes outstanding total $805,000, with a history of note conversions diluting equity.

Use of proceeds and capital allocation

• Company will not receive proceeds from the resale of shares by the selling stockholder; net proceeds from the primary offering (up to $1.165 million) will be used for R&D, clinical trials, and general corporate purposes.

• Management has broad discretion over use of funds, with a stated need to raise at least $3.7 million to fund operations for the next 15 months.

• Additional capital requirements for clinical development of lead candidates are estimated at $30–35 million.